

Lopinavir+Ritonavir+Ribavirina+Interferone beta-1b vs Lopinavir+Ritonavir for COVID-19

Author(s): Cruciani F, De Crescenzo F, Vecchi S, Saulle R, Mitrova Z, Amato L, Davoli M.

Question: Should Lopinavir+ritonavir+ribavirina+interferon beta-1b vs lopinavir+ritonavir be used for COVID-19?

Setting: Inpatient

Certainty assessment							№ of patients		Effect		Certainty
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Lopinavir+ritonavir+ri bavirina+interferon beta-1b	lopinavir+ritonavir	Relative (95% CI)	Absolute (95% CI)	
Number of patients with adverse events											
1 ¹	randomised trials	very serious _a	not serious	not serious	very serious _b	none	41/86 (47.7%)	20/41 (48.8%)	RR 0.98 (0.67 to 1.43)	10 fewer per 1.000 (from 161 fewer to 210 more)	⊕○○○ VERY LOW
Number of patients with severe adverse events											
1 ¹	randomised trials	very serious _a	not serious	not serious	very serious _b	none	0/86 (0.0%)	1/41 (2.4%)	RR 0.16 (0.01 to 3.87)	20 fewer per 1.000 (from 24 fewer to 70 more)	⊕○○○ VERY LOW
Mortality at 30 days follow up											
1 ¹	randomised trials	very serious _a	not serious	not serious	very serious _b	none					⊕○○○ VERY LOW
Time SARS-CoV-2 clearance											
1	randomised trials	very serious _a	not serious	not serious	very serious _b	none	The group lopinavir / ritonavir + ribavirin and interferon beta-1C had a significantly shorter median time (7 days [IQR 5-11]) than the control group (12 days [8-15]; HR 4.37 [95% CI 1.86-10.24], p = 0.0010			⊕○○○ VERY LOW	
Length of hospitalization											
1	randomised trials	very serious _a	not serious	not serious	very serious _b	none	The median length of stay in hospital was shorter in the lopinavir / ritonavir + ribavirin and interferon beta-1C group than in the lopinavir / returnavir control group only (9 days [7-13] vs 14.5 days [9, 3-16]; HR 2.72 [1.2-6.13], p = 0.016).			⊕○○○ VERY LOW	

CI: Confidence interval; **RR:** Risk ratio; **HR:** Hazard Ratio

Explanations

a. Downgraded of two levels for high risk of selection, performance and detection bias

b. Downgraded of two levels for very small sample size

References

1. Hung, Ivan Fan-Ngai, Lung, Kwok-Cheung, al., Eugene Yuk-Keung Tso et. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet; 2020.